NCT03649581Recruiting
Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
Investigation of Clinical, Cognitive and Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
Source: ClinicalTrials.gov · Last updated 3 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The current diagnostic criteria for schizophrenia and other psychotic disorders are relatively broad and lack precision. Therefore, distinct diseases may be grouped together under the same diagnostic category, although these diseases may differ according to their clinical expression, prognosis and perhaps their physiopathological causes. We think that identifying subforms of psychotic disorders that are more homogeneous will better enable to understand their respective physiopathological causes and find personalized treatments. This study will compare two subforms of psychotic disorders that have been clinically distinguished in the 1970s. These phenotypes have however not been validated yet using scientific investigations. Using clinical assessments, cognitive evaluations and neurophysiological measures (fMRI) investigating the domains of affect and psychomotoricity , we expect that these two subforms will differ on their clinical, cognitive and neurophysiological characteristics, namely: hebephrenia will be associated with deficits on the affect markers , and respect psychomotoricity (catatonia scales, tests assessing movement planification) whereas the opposite pattern will be observed for periodic catatonia.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- First submitted
- 21 Aug 2018
- Start date
- 28 Feb 2019
- Primary completion date
- 2 Feb 2027
- Lead sponsor
- University Hospital, Strasbourg, France
- Diseases
- Schizophrenia
- NCT number
- NCT03649581
What you commit to
- Study type: Interventional
- Planned participants: 84
- From 28 Feb 2019 to the primary completion date, 2 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- neurological history (epilepsia, brain injury, brain surgery…)
Other illness
- current severe or unstable somatic illness
- current substance use disorder (DSM-5)
- current major depressive disorder (DSM-5)
Other
- for both patients and controls
- mental retardation (IQ \< 70)
- pregnancy, breast feeding
- current legal control
- contra-indication for fMRI for controls only psychotropic intake during the last 3 weeks
Who the study is looking for
- for both patients and controls
- male or female willing to participate and who have signed up the legal document
- under the protection of health insurance for patients only
- schizophrenia or schizo-affective disorder according to the DSM-5 criteria
- periodic catatonia or hebephrenia accordin to WKL classification
- clinically stable for at least 2 months
- in or out patients for controls only
- no psychiatric history
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Service de Psychiatrie I, Hôpital Civil, Hôpitaux Universitaires de Strasbourg Coordinator of this site? Confirm its status | Strasbourg | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.